Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF InhibitionHélène Salmon, Miriam Mérad, Brandon Hogstad et al.|Immunity|2016Cited by 1.2k
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L. Crombie, Michael Dickinson, Tara Graff et al.|Blood|2024Cited by 132
Bispecific antibody targeting of lipid nanoparticlesAngelo Amabile, Brian D. Brown, Zhe Yu et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 10
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growthJaime Mateus-Tique, Brian D. Brown, Ashwitha Lakshmi et al.|Cancer Cell|2026Cited by 5
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumorsMatthew Lin, Joshua Brody, Joanna K Chorazeczewski et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0